These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 16836302)

  • 1. cis-1-Amino-2-indanol in drug design and applications to asymmetric processes.
    Gallou I; Senanayake CH
    Chem Rev; 2006 Jul; 106(7):2843-74. PubMed ID: 16836302
    [No Abstract]   [Full Text] [Related]  

  • 2. Stereoselective synthesis of 3-aminoindan-1-ones and subsequent incorporation into HIV-1 protease inhibitors.
    Arefalk A; Wannberg J; Larhed M; Hallberg A
    J Org Chem; 2006 Feb; 71(3):1265-8. PubMed ID: 16438552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure-guided design of C2-symmetric HIV-1 protease inhibitors based on a pyrrolidine scaffold.
    Blum A; Böttcher J; Heine A; Klebe G; Diederich WE
    J Med Chem; 2008 Apr; 51(7):2078-87. PubMed ID: 18348517
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Design, synthesis, evaluation, and crystallographic-based structural studies of HIV-1 protease inhibitors with reduced response to the V82A mutation.
    Clemente JC; Robbins A; Graña P; Paleo MR; Correa JF; Villaverde MC; Sardina FJ; Govindasamy L; Agbandje-McKenna M; McKenna R; Dunn BM; Sussman F
    J Med Chem; 2008 Feb; 51(4):852-60. PubMed ID: 18215016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of sulfoximine based inhibitors for HIV-1 protease.
    Raza A; Sham YY; Vince R
    Bioorg Med Chem Lett; 2008 Oct; 18(20):5406-10. PubMed ID: 18829317
    [TBL] [Abstract][Full Text] [Related]  

  • 6. An old target revisited: two new privileged skeletons and an unexpected binding mode for HIV-protease inhibitors.
    Specker E; Böttcher J; Lilie H; Heine A; Schoop A; Müller G; Griebenow N; Klebe G
    Angew Chem Int Ed Engl; 2005 May; 44(20):3140-4. PubMed ID: 15822136
    [No Abstract]   [Full Text] [Related]  

  • 7. Asymmetric synthesis of the potent HIV-protease inhibitor, nelfinavir.
    Raghavan S; Krishnaiah V; Sridhar B
    J Org Chem; 2010 Jan; 75(2):498-501. PubMed ID: 20000659
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery of potent HIV-1 protease inhibitors incorporating sulfoximine functionality.
    Lu D; Vince R
    Bioorg Med Chem Lett; 2007 Oct; 17(20):5614-9. PubMed ID: 17822899
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Structure-activity relationships of novel HIV-1 protease inhibitors containing the 3-amino-2-chlorobenzoyl-allophenylnorstatine structure.
    Mimoto T; Nojima S; Terashima K; Takaku H; Shintani M; Hayashi H
    Bioorg Med Chem; 2008 Feb; 16(3):1299-308. PubMed ID: 17981045
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting the open-flap conformation of HIV-1 protease with pyrrolidine-based inhibitors.
    Böttcher J; Blum A; Dörr S; Heine A; Diederich WE; Klebe G
    ChemMedChem; 2008 Sep; 3(9):1337-44. PubMed ID: 18720485
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-speed synthesis of potent C2-symmetric HIV-1 protease inhibitors by in-situ aminocarbonylations.
    Wannberg J; Kaiser NF; Vrang L; Samuelsson B; Larhed M; Hallberg A
    J Comb Chem; 2005; 7(4):611-7. PubMed ID: 16004505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Design, synthesis and structure-activity study of shorter hexa peptide analogues as HIV-1 protease inhibitors.
    Narendra Babu SN; Rangappa KS
    Bioorg Med Chem; 2008 Jan; 16(2):874-80. PubMed ID: 17981043
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Drug design: new inhibitors for HIV-1 protease based on Nelfinavir as lead.
    Perez MA; Fernandes PA; Ramos MJ
    J Mol Graph Model; 2007 Oct; 26(3):634-42. PubMed ID: 17459746
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alpha-aminoalkyl-alpha'-halomethylketones: Preparation and application to pharmaceutically interesting compounds.
    Reeder MR; Anderson RM
    Chem Rev; 2006 Jul; 106(7):2828-42. PubMed ID: 16836301
    [No Abstract]   [Full Text] [Related]  

  • 15. Directed reductive amination of beta-hydroxy-ketones: convergent assembly of the ritonavir/lopinavir core.
    Menche D; Arikan F; Li J; Rudolph S
    Org Lett; 2007 Jan; 9(2):267-70. PubMed ID: 17217281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combination of non-natural D-amino acid derivatives and allophenylnorstatine-dimethylthioproline scaffold in HIV protease inhibitors have high efficacy in mutant HIV.
    Nakatani S; Hidaka K; Ami E; Nakahara K; Sato A; Nguyen JT; Hamada Y; Hori Y; Ohnishi N; Nagai A; Kimura T; Hayashi Y; Kiso Y
    J Med Chem; 2008 May; 51(10):2992-3004. PubMed ID: 18426195
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Discovery of HIV-1 protease inhibitors with picomolar affinities incorporating N-aryl-oxazolidinone-5-carboxamides as novel P2 ligands.
    Ali A; Reddy GS; Cao H; Anjum SG; Nalam MN; Schiffer CA; Rana TM
    J Med Chem; 2006 Dec; 49(25):7342-56. PubMed ID: 17149864
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Industrial syntheses of the central core molecules of HIV protease inhibitors.
    Izawa K; Onishi T
    Chem Rev; 2006 Jul; 106(7):2811-27. PubMed ID: 16836300
    [No Abstract]   [Full Text] [Related]  

  • 19. Design of HIV protease inhibitors based on inorganic polyhedral metallacarboranes.
    Rezácová P; Pokorná J; Brynda J; Kozísek M; Cígler P; Lepsík M; Fanfrlík J; Rezác J; Grantz Sasková K; Sieglová I; Plesek J; Sícha V; Grüner B; Oberwinkler H; Sedlácek' J; Kräusslich HG; Hobza P; Král V; Konvalinka J
    J Med Chem; 2009 Nov; 52(22):7132-41. PubMed ID: 19874035
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synthesis of enantiomerically pure trans-(1R,2R)- and cis-(1S,2R)-1-amino-2-indanol by lipase and omega-transaminase.
    Yun H; Kim J; Kinnera K; Kim BG
    Biotechnol Bioeng; 2006 Feb; 93(2):391-5. PubMed ID: 16302257
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.